South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

More than two weeks after President Donald Trump said he would halt “all payments” to Colombia, there has not been any interruption to the assistance, even after the administration sanctioned the ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

The Lupus Research Alliance (LRA), through its Lupus Accelerating Breakthroughs Consortium (Lupus ABC)—a public-private ...

But Pfizer (PFE) isn't going down without a fight. While Novo Nordisk's (NVO) bid could top Pfizer's by up to $2.7 billion, Pfizer Chief Executive Albert Bourla called it "illusory" and said it can't ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Lab equipment maker Waters Corp raised its annual profit forecast on Tuesday, after beating third-quarter profit estimates on ...

China on Tuesday defended its growing cooperation with Venezuela, saying that its engagement with leader Nicolás Maduro’s government “constitutes normal cooperation between sovereign states” and is ...

Why hadn’t I been able to save my son? What biological mechanisms made him so relentlessly ill? Could more effective ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.